CAR T Therapy Scores Another Win as FDA Approves Kite’s Yescarta
- Posted by ISPE Boston
- On October 23, 2017
Kite Pharma, acquired by Gilead Sciences in October 2016 for $11.9 billion, has announced that the FDA has granted approval to Yescarta™ (axicabtagene ciloleucel), a CAR T (chimeric antigen receptor T cell) cancer therapy. CAR T therapy is a breakthrough in hematologic cancer treatment in which a patient’s own T cells are engineered to seek […]
Read More